NCT07215663View on ClinicalTrials.gov

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2028

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

Cizutamig

Cizutamig will be dosed according to the protocol

Sponsors
All Listed Sponsors
lead

Candid Therapeutics

INDUSTRY

NCT07215663 - Clinical Study of Cizutamig in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter